Octreotide Acetate for Injectable Suspension, for gluteal intramuscular use, 30 mg, In Single-Dose kits containing: 8-mL vial of 30 mg strength, a pre-filled syringe containing 2 mL of diluent, one vial adapter, and one sterile 1® 19-gauge safety injection needle, Rx only, Manufactured in Greece BY: Pharmathen International S.A, Rodopi, 69300 Greece, Manufactured For: TEVA Pharmaceuticals, Parsippany, NJ 07054. NDC Kit Carton: 0480-9262-08; Vial Label: 0480-9260-01; Tray Label: 0480-9262-08; Diluent Label: 0480-9263-21.
Published May 13, 2026 · Recall initiated: April 24, 2026
Summary
FDA records drug Class II recall D-0519-2026, published May 13, 2026 and initiated April 24, 2026. Recalling firm: Teva Pharmaceuticals USA, Inc; Status: Ongoing; Reported quantity: 2,200 kits; Lot: Lot: 45011002, Exp. 03/31/2027. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Lack of Assurance of Sterility: Quality system deficiencies identified during a routine U.S Food and Drug Administration (FDA) inspection at the contract manufacturer.
What to do
Voluntary: Firm initiated · Letter
Get an email if OCTREOTIDE ACETATE has another recall
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Brand
- OCTREOTIDE ACETATE
- Manufacturer
- Teva Pharmaceuticals USA, Inc
- Distributor
- Nationwide in the USA
- Lot
- Lot: 45011002, Exp. 03/31/2027
- Risk classification
- Class II
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDABD PurPrep, Povidone-iodine 8.3% w/w (0.83% available iodine) with isopropyl alcohol 72.5% w/w SterileMay 13, 2026
- FDAEnalapril Maleate Tablets, USP, 20 mg, 1,000-count bottle, Rx only, Manufactured by: Unique PharmaceuticalMay 13, 2026
- FDAOctreotide Acetate for Injectable Suspension, for gluteal intramuscular use, 10 mg, Single-dose 8 mL vial inApril 1, 2026
- FDAOctreotide Acetate for Injectable Suspension, for gluteal intramuscular use, 20 mg, Single-dose 8 mL vial inApril 1, 2026
- FDAOctreotide Acetate for Injectable Suspension, for gluteal intramuscular use, 30 mg, Single-dose 8 mL vial inApril 1, 2026
- FDAOctreotide Acetate Injection 500 mcg/mL, 10 x 1 mL Single-Dose Unit-of-Use Syringes, For Subcutaneous orNovember 16, 2022
Questions about this recall
Was Octreotide Acetate for Injectable Suspension, for gluteal intramuscular use, 30 mg, In Single-Dose kits containing: 8-mL vial of 30 mg strength, a pre-filled syringe containing 2 mL of diluent, one vial adapter, and one sterile 1® 19-gauge safety injection needle, Rx only, Manufactured in Greece BY: Pharmathen International S.A, Rodopi, 69300 Greece, Manufactured For: TEVA Pharmaceuticals, Parsippany, NJ 07054. NDC Kit Carton: 0480-9262-08; Vial Label: 0480-9260-01; Tray Label: 0480-9262-08; Diluent Label: 0480-9263-21. recalled?
Yes. FDA published recall D-0519-2026 on May 13, 2026. Reported hazard: Lack of Assurance of Sterility: Quality system deficiencies identified during a routine U.S Food and Drug Administration (FDA) inspection at the contract manufacturer.
What should I do if I have this product?
Voluntary: Firm initiated · Letter
How do I know if my unit is part of the recall?
Compare your product details with the notice. Brand: OCTREOTIDE ACETATE.